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CKD and cannabinoid 
antagonists in obese 
animals
Severe obesity is associated with chronic 
kidney disease (CKD) in humans and 
animal models. Since the development 
of speciﬁc blockers of cannabinoid 
receptors, a number of studies in 
humans and animals have shown that 
such blockades often improve obesity. 
As they report in this issue, Janiak et 
al. studied the role of the cannabinoid 
receptor CB1 in obesity and CKD-
related mortality in obese Zucker rats. 
Using a cannabinoid CB1 receptor 
antagonist, they found that pair-fed 
obese rats sustained a decrease in 
body weight, transient reduction in 
food intake, and an increase in plasma 
adiponectin, as well as longer survival. 
Also, plasma lipids, proteinuria, 
excretion of N-acetylglucosaminidase, 
and a variety of metabolic factors 
were lower in the pair-fed rats. All 
the signs of renal damage, such as 
lower glomerular ﬁltration rate, were 
attenuated. These important studies 
suggest that cannabinoid receptors 
play a critical role in the pathogenesis 
of obesity and/or its secondary 
complications. See page 1345.
VEGF receptor 
blockade in PKD
Vascular endothelial growth factor 
(VEGF) signals through a number 
of tyrosine kinase receptors that are 
primarily located in endothelial cells. 
However, recent studies show that 
these receptors are also present in 
tubular epithelial cells, implying that 
VEGF could play a role in regulation 
of tubular function. In new research, 
Tao et al. found increased levels of 
VEGF in the plasma of Han:SPRD 
rats with polycystic kidney disease 
(PKD). They then found that the 
tubular epithelial cells lining the 
cysts expressed two VEGF receptors 
at higher levels than in normal 
animals. Considering that receptor 
tyrosine kinases are often involved 
in pathways of cell proliferation, the 
authors infused the animals with 
ribozymes that speciﬁcally inhibited 
VEGFR1 and VEGFR2 mRNA 
expression. They found that tubule-
cell proliferation within the cysts 
was signiﬁcantly decreased in the 
ribozyme-treated animals, leading 
to decreased cystogenesis, blunted 
renal enlargement, and prevention 
of the loss of renal function. Because 
generation of small-molecule 
inhibitors of VEGF receptors is an 
important target in pharmacology, it 
is likely that drugs performing this 
function will soon become available. 
At that time, it will be interesting to 
see whether the phenomena found to 
occur in rats with PKD are replicated 
in human PKD. See page 1358.
Thiazolidinediones  
in albuminuria of 
diabetes
While thiazolidinediones are well 
known to have insulin-sensitizing 
effects, findings that suggest other 
beneficial effects of the drug class 
have raised increasing interest. Such 
effects include improvement in 
plasma lipid profiles and reduction 
in inflammation. In a new study, 
Miyazaki et al. examine whether 
rosiglitazone improves or prevents 
proteinuria in diabetic patients. 
After 3 months of observation, 
the urinary albumin-to-creatinine 
ratio in diabetic patients taking 
the drug significantly decreased as 
compared with that in the control 
group of diabetic patients on placebo. 
Detailed metabolic studies showed 
that rosiglitazone improved glucose 
utilization, as expected. In addition, 
rosiglitazone treatment significantly 
decreased fasting free fatty acid and 
tumor necrosis factor-α levels, and it 
significantly increased adiponectin 
concentrations. Reduced albuminuria 
correlated with improved metabolic 
profiles. However, it is still not clear 
whether such improvements were 
due primarily to improved insulin 
sensitivity or to another effect that 
this class of drugs may have on 
separate pathways. See page 1367.
